Allergologie Select最新文献

{"title":"Status report on the atopic dermatitis registry TREATgermany.","authors":"Doreen Siegels,&nbsp;Eva Haufe,&nbsp;Luise Heinrich,&nbsp;Thomas Werfel,&nbsp;Stephan Weidinger,&nbsp;Jochen Schmitt","doi":"10.5414/ALX02262E","DOIUrl":"https://doi.org/10.5414/ALX02262E","url":null,"abstract":"<p><strong>Background: </strong>The TREATgermany registry collects data from children, adolescents, and adults with moderate-to-severe atopic dermatitis (AD) in Germany. For this purpose, clinical and patient-reported outcomes, the course of the disease, and applied therapies are observed.</p><p><strong>Methods: </strong>TREATgermany recruits patients with moderate-to-severe AD according to the diagnostic criteria of the UK Working Party, an \"Objective Scoring for Atopic Dermatitis\" (oSCORAD) > 20 and/or currently antiinflammatory systemic treatment for AD or previous anti-inflammatory systemic treatment for AD within past 24 months before inclusion. No study related interventions will be performed. Currently, 59 dermatological practices, clinics, and university hospitals are participating in TREATgermany (as of May 2021). Based on the interim analysis of October 13, 2020, patient characteristics were described from 4,373 documented visits of adult participants (n = 1,025).</p><p><strong>Results: </strong>The mean age at inclusion in TREATgermany was 42 years, 57.7% of patients were men (n = 591) and 42.3% were women (n = 434). According to oSCORAD, 85.8% of those included suffered from moderate-to-severe AD. At baseline visit, 744 patients had already received one or more systemic treatments for AD (glucocorticosteroids n = 600, ciclosporin A (CSA) n = 307, dupilumab n = 98). 597 patients received dupilumab during their participation in TREATgermany, 134 patients received CSA.</p><p><strong>Conclusion: </strong>With the increasing number of recruitment centers (October 2020: 38 centers; May 2021: 59 centers), TREATgermany can continue to make an important contribution to health services research for patients with moderate-to-severe AD. The registry fulfills the methodological requirements of IQWiG for the collection and processing of healthcare-related data. With the successful and expected approval of further systemic treatments, these can be compared in terms of efficacy and safety in the future. In addition, with the recruitment of children and adolescents started in 2021, this patient group can also be observed.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"5 ","pages":"274-286"},"PeriodicalIF":0.0,"publicationDate":"2021-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39424711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-inflammatory topical medication - new developments in the treatment of atopic dermatitis.","authors":"Johannes Wohlrab,&nbsp;Burkhard Kreft,&nbsp;Luisa Sophie Scholz","doi":"10.5414/ALX02255E","DOIUrl":"https://doi.org/10.5414/ALX02255E","url":null,"abstract":"<p><p>Atopic dermatitis is a chronic inflammatory disease that arises from polygenic disposition, a dysfunction of the physicochemical epithelial barrier, a cutaneous dysbiosis, and a faulty neurosensory activity and shows a highly individual acuity due to epigenetic factors. An essential component of therapeutic management is the application of anti-inflammatory topical medication. Currently, topical glucocorticoids and topical calcineurin inhibitors are routinely used in reactive and proactive therapy. In recent years, the development of molecular medicine has identified several new therapeutic targets that have enabled the development of innovative therapeutic approaches. In addition to phosphodiesterase-4 inhibitors and aryl hydrocarbon receptor modulators, it is mainly Janus kinase inhibitors with different selectivity that are emerging as new effective and safe options for topical therapy. The current data suggests that in the coming months and years representatives of the above-mentioned substance classes will be approved for topical use.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"5 ","pages":"260-264"},"PeriodicalIF":0.0,"publicationDate":"2021-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39424709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new era has begun: Treatment of atopic dermatitis with biologics.","authors":"Dora Stölzl,&nbsp;Stephan Weidinger,&nbsp;Katharina Drerup","doi":"10.5414/ALX02259E","DOIUrl":"https://doi.org/10.5414/ALX02259E","url":null,"abstract":"<p><p>The era of biologics for the treatment of moderate-to-severe atopic dermatitis (AD) began in 2017 with the approval of dupilumab, a monoclonal antibody that binds to the α-subunit of the interleukin IL-4 receptor. Until then, only conventional immunosuppressants were available for systemic treatment, of which only cyclosporine is approved for the treatment of severe AD. In the meantime, the therapeutic landscape of AD has been changing rapidly, and additional biologics have been developed which target IL-13, the IL-31 receptor, OX40, and OX40L, among others. Many of these substances have already shown promising results in phase 1, 2, and in some cases also phase 3 trials. In June 2021, tralokinumab, an IL-13 antibody, has been approved in Europe for the treatment of moderate-to-severe AD in adults. In addition to antibody-based therapies, \"small molecules\" that, e.g., inhibit Janus kinases enrich the armamentarium of systemic AD therapies. With all these agents, not only will many more targeted therapies become available, but also will the complex and heterogeneous pathophysiological processes of this disease be better understood.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"5 ","pages":"265-273"},"PeriodicalIF":0.0,"publicationDate":"2021-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39424710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barrier defect in atopic dermatitis - possibilities and limits of basic skin therapy.","authors":"Lennart M Roesner,&nbsp;Annice Heratizadeh","doi":"10.5414/ALX02268E","DOIUrl":"https://doi.org/10.5414/ALX02268E","url":null,"abstract":"<p><p>The increased permeability of the skin barrier towards environmental factors such as allergens is considered a key factor in the pathogenesis of atopic dermatitis (AD). Strengthening the skin barrier through basic skin therapy represents the basis of any therapy for AD. It is well known that genetic factors as well as the skin inflammation itself contribute to the weakening of the barrier; here, recent studies have led to a deeper understanding of the complex structures of the epidermis. The possibility of counteracting the disease preventively by the use of basic skin therapy from birth on has been studied intensively in recent years. This article summarizes recent findings on the effects of basic skin therapy as a primary and secondary preventive measure.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"5 ","pages":"287-292"},"PeriodicalIF":0.0,"publicationDate":"2021-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439110/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39424712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 vaccination and allergen immunotherapy (AIT) - A position paper of the German Society for Applied Allergology (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI).","authors":"Ludger Klimek,&nbsp;Oliver Pfaar,&nbsp;Eckard Hamelmann,&nbsp;Jörg Kleine-Tebbe,&nbsp;Christian Taube,&nbsp;Martin Wagenmann,&nbsp;Thomas Werfel,&nbsp;Randolf Brehler,&nbsp;Natalija Novak,&nbsp;Norbert Mülleneisen,&nbsp;Sven Becker,&nbsp;Margitta Worm","doi":"10.5414/ALX02245E","DOIUrl":"https://doi.org/10.5414/ALX02245E","url":null,"abstract":"<p><strong>Background: </strong>Vaccinations against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are intended to induce an immune response to protect against infection/disease. Allergen immunotherapy (AIT) is thought to induce a (different) immune response, e.g., to induce tolerance to allergens. In this position paper we clarify how to use AIT in temporal relation to COVID-19 vaccination. Four SARS-CoV-2 vaccines are currently approved in the EU, and their possible immunological interactions with AIT are described together with practical recommendations for use.</p><p><strong>Materials and methods: </strong>Based on the internationally published literature, this position paper provides specific recommendations for the use of AIT in temporal relation to a SARS-CoV-2 vaccination.</p><p><strong>Results: </strong>AIT is used in 1) allergic rhinitis, 2) allergic bronchial asthma, 3) insect venom allergy, 4) food allergy (peanut).</p><p><strong>Conclusion: </strong>For the continuation of an ongoing AIT, we recommend an interval of 1 week before and after vaccination for subcutaneous immunotherapy (SCIT). For sublingual immunotherapy (SLIT) and oral immunotherapy (OIT), we recommend taking them up to the day before vaccination and a break of 2 - 7 days after vaccination. Initiation of a new SCIT, SLIT, or OIT should be delayed until 1 week after the day of the second vaccination. For SCIT, we generally recommend an interval of ~ 1 week to COVID-19 vaccination.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"5 ","pages":"251-259"},"PeriodicalIF":0.0,"publicationDate":"2021-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39445908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atopic eczema is an environmental disease.","authors":"Daria Luschkova, Katharina Zeiser, Alika Ludwig, Claudia Traidl-Hoffmann","doi":"10.5414/ALX02258E","DOIUrl":"10.5414/ALX02258E","url":null,"abstract":"<p><p>It is obvious that social, biogenic, and anthropogenic environmental factors, as well as nutrition contribute to the development and course of atopic eczema. Social deprivation and stress have a negative impact on atopic eczema symptoms, and social change in recent decades has led to a \"westernized\" lifestyle associated with high prevalence of atopic eczema in industrialized countries. Urbanization leads to an increase in air pollution and a decrease in biodiversity, which negatively affects atopic eczema. Climate change alters the allergenicity of pollen, which increases atopic eczema symptoms in some patients during the pollen season. Protective natural and social factors for the prevention of atopic eczema and for the promotion of \"climate resilience\" should be given greater consideration in future research.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"5 ","pages":"244-250"},"PeriodicalIF":0.0,"publicationDate":"2021-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39380923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update of the S2k guideline on the management of IgE-mediated food allergies.","authors":"Margitta Worm,&nbsp;Imke Reese,&nbsp;Barbara Ballmer-Weber,&nbsp;Kirsten Beyer,&nbsp;Stephan C Bischoff,&nbsp;Barbara Bohle,&nbsp;Knut Brockow,&nbsp;Martin Claßen,&nbsp;Peter J Fischer,&nbsp;Eckard Hamelmann,&nbsp;Uta Jappe,&nbsp;Jörg Kleine-Tebbe,&nbsp;Ludger Klimek,&nbsp;Berthold Koletzko,&nbsp;Lars Lange,&nbsp;Susanne Lau,&nbsp;Ute Lepp,&nbsp;Vera Mahler,&nbsp;Katja Nemat,&nbsp;Martin Raithel,&nbsp;Joachim Saloga,&nbsp;Christiane Schäfer,&nbsp;Sabine Schnadt,&nbsp;Jens Schreiber,&nbsp;Zsolt Szépfalusi,&nbsp;Regina Treudler,&nbsp;Martin Wagenmann,&nbsp;Thomas Werfel,&nbsp;Torsten Zuberbier","doi":"10.5414/ALX02257E","DOIUrl":"10.5414/ALX02257E","url":null,"abstract":"<p><p>Not available.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"5 ","pages":"195-243"},"PeriodicalIF":0.0,"publicationDate":"2021-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39185118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between allergic rhinitis and diamine oxidase activity: A preliminary report.","authors":"Miguel Mayo-Yáñez, Andrea Díaz-Díaz, Juan C Vázquez-Barro, Jesús Herranz González-Botas, Angélica Figueroa, Carlos S Martín-Martín","doi":"10.5414/ALS400537","DOIUrl":"10.5414/ALS400537","url":null,"abstract":"<p><strong>Aim: </strong>To analyze the diamine oxidase (DAO), the main catabolic enzyme of histamine, degradation activity and its relation with symptoms of persistent allergic rhinitis.</p><p><strong>Methods: </strong>In this descriptive and analytical observational study, we collected DAO activity levels and the nasal peak inspiratory flow.</p><p><strong>Results: </strong>Enzymatic activity deficit in 108 patients was 46.3% (95% CI, 0.44 - 0.63), 33.33% in mild and 47.92% in moderate/severe rhinitis (p = 0.376). The nasal peak inspiratory flow in patients with a deficit in DAO activity was 76.30 ± 28.40 L/min compared to 93.62 ± 37.50 L/min in patients with normal enzymatic activity (p = 0.010).</p><p><strong>Conclusions: </strong>It seems that the lower the catabolic activity of DAO, the lower the nasal peak inspiratory flow observed. Although DAO activity levels could be a severity biomarker in allergic rhinitis, a cause-effect association cannot be concluded. The enzyme could be another actor in the pathophysiology of allergic rhinitis.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"5 ","pages":"187-194"},"PeriodicalIF":0.0,"publicationDate":"2021-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39162961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergic bronchopulmonary aspergillosis (ABPA) in an atopic patient with difficult-to-expectorate airway secretions.","authors":"Marcus Joest","doi":"10.5414/ALX02200E","DOIUrl":"https://doi.org/10.5414/ALX02200E","url":null,"abstract":"<p><p>In the workup of a 55-year-old atopic patient with cough and viscous secretions, we diagnosed an allergic bronchopulmonary aspergillosis (ABPA) on the basis of common diagnostic criteria for adult asthma patients (Rosenberg-Patterson and ISHAM), supported by the use of IgE antibodies against the Aspergillus components Asp f 2, f 4, and f 6. Initial treatment with prednisolone and itraconazole led to remission. In the long-term follow-up, there were few relapses until 2015, which responded well to standard treatment with oral steroids, and since 2016 the patient is in stable remission. The case highlights the valuable contribution of Aspergillus IgE measurements, including the specific IgEs against the components Asp f 1, f 2, f 4, and f 6 in the diagnosis of ABPA.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"5 ","pages":"157-161"},"PeriodicalIF":0.0,"publicationDate":"2021-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167735/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38987263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular allergy diagnosis using pollen marker allergens and pollen panallergens: Five patterns seen in multiple test reactions to pollen extracts.","authors":"Jörg Kleine-Tebbe,&nbsp;Juliane Ackermann-Simon,&nbsp;Gerald Hanf","doi":"10.5414/ALX02238E","DOIUrl":"https://doi.org/10.5414/ALX02238E","url":null,"abstract":"<p><p>Polysensitizations to tree, grass, and weed pollen are found in ~ 20% of pollen-allergic individuals. They are often based on broad IgE cross-reactivities to pollen panallergens belonging to highly conserved protein families: 1. profilins, 2. polcalcins (calcium-binding proteins in pollen), 3. cyclophilins. They represent highly conserved cross-reactive minor allergens present in all pollen species, but also in plant foods and other organisms. Despite being rarely clinically relevant they can hamper allergy diagnostic tests with extracts. In this situation, molecular allergy diagnosis is able to distinguish broad cross-reactivity due to allergen-specific IgE to pollen panallergens (i.e. profilins Bet v 2 or Phl p 12; polcalcins Bet v 4 or Phl p 7; and, in the future, cyclophilins Bet v 7 or Ole e 15) from primary IgE sensitizations to so-called marker allergens represented by important pollen major allergens: Bet v 1 for the birch and beech family (<i>Fagales</i>), Ole e 1 for olive and ash (<i>Oleaceae</i>), Phl p 1 for temperate climate grasses (<i>Poaceae</i>), Art v 1 for mugwort (<i>Artemisia</i>), Amb a 1 for Ambrosia species (<i>Ambrosia</i>). Five typical cases (A - E) with positive skin prick test results to tree, grass, and weed pollen extracts demonstrate typical patterns of IgE sensitization with a variable impact of pollen panallergens: A - profilins, B - polcalcins, C - profilins and polcalcins, D - presumably cyclophilins, E - primary polysensitization to tree, grass, and weed pollen without interference from profilins or polcalcins. Differences between pollen extract-based skin prick test diagnosis and molecular allergen-specific IgE testing are explained using the presented concept. This approach allows to reduce the number of allergen extracts - presuming they are also clinically relevant - for allergen immunotherapy (i.e., only tree and/or grass pollen extracts), particularly in pollen-polysensitized patients.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"5 ","pages":"180-186"},"PeriodicalIF":0.0,"publicationDate":"2021-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38987264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}